Gallant Welcomes New Board Members to Advance Pet Health Solutions
As Gallant moves forward with its mission to deliver potentially the first FDA-approved, ready-to-use stem cell therapy for pets, the company has announced the appointment of Dr. Misti Ushio and Doug Drew to its Board of Directors. Their extensive experience in biotechnology and veterinary operations will be crucial as the company embarks on this exciting journey.
Expertise in Biotech and Veterinary Innovation
Gallant, a pioneering animal health biotechnology company, is at the forefront of developing ready-to-use stem cell therapies targeting a range of pet health challenges. The new board members, Dr. Ushio and Mr. Drew, bring decades of experience that will enhance Gallant’s efforts in bringing innovative therapies to market.
Introducing Dr. Misti Ushio
Dr. Misti Ushio, currently a Managing Partner at Digitalis Ventures, is recognized for her substantial contribution to the biotechnology landscape. With over 25 years of experience, Dr. Ushio has a successful track record in translating groundbreaking scientific discoveries into commercially viable products. She has previously held key leadership roles, including founding CEO of TARA Biosystems, where she played a pivotal role in the development of innovative therapies and was instrumental in the company's growth and eventual acquisition.
Dr. Ushio stated, "Building a new therapeutic category requires talent, technology, and a great deal of passion. Gallant has it all. As an investor, I've been impressed by how quickly the team is advancing this therapy through clinical trials and the FDA process. I am excited to contribute more directly as they prepare to enter the market, shifting the focus from managing symptoms to addressing disease at its source."
Welcoming Doug Drew
Doug Drew joins Gallant with a wealth of experience, having served as the Global President of Mars Veterinary Health. His leadership expanded a network of veterinary hospitals globally while promoting diversity and operational excellence among veterinary professionals. Drew is known for his ability to integrate innovation within clinical workflows tailored to meet the practical needs of veterinarians.
He shared his enthusiasm for Gallant’s achievements, stating, "Gallant’s therapy addresses a significant gap in veterinary medicine—it’s ready to use, simple to administer, and will greatly benefit pets with various underserved conditions. I look forward to contributing to a company that is making regenerative medicine an integral part of routine veterinary care."
Strategic Timing for Gallant
The timing of these appointments comes as Gallant progresses following a significant $18 million Series B financing round and an important milestone from the FDA. The FDA has acknowledged the viability of Gallant’s ready-to-use stem cell therapy for treating refractory Feline Chronic Gingivostomatitis (FCGS), which is a critical step in the approval process, with anticipation of a final decision as early as early 2026.
Dr. Linda Black, CEO of Gallant, expressed her confidence in the new board members, remarking, "Misti and Doug are exceptional leaders whose experiences reflect the dual pillars of our mission—scientific excellence and practical impact. Their guidance is invaluable as we transition towards commercialization. We are privileged to have them aboard as we strive to enhance pet health care."
About Gallant
Gallant is revolutionizing animal health with a new line of veterinary medicine focused on ready-to-use stem cell therapies. By addressing the root causes of diseases in pets, Gallant's innovative approach marks a significant departure from traditional symptom-management practices. With leaders in veterinary regenerative medicine, the company is well-positioned to bring transformative solutions to the market, enhancing the quality of care available to pet owners. For further insights into Gallant's approach and products, please visit their website.
Frequently Asked Questions
What is Gallant's primary focus?
Gallant aims to create a new category of veterinary medicine through ready-to-use stem cell therapies targeting disease causes in pets.
Who are the new members of Gallant's Board of Directors?
The new board members are Dr. Misti Ushio and Doug Drew, both with extensive experience in biotechnology and veterinary health.
Why is the timing significant for Gallant?
The appointments coincide with critical FDA milestones and substantial funding, positioning the company for successful product launches in the near future.
What experience does Dr. Misti Ushio bring to Gallant?
Dr. Ushio has over 25 years in biotechnology, focusing on translating scientific advancements into commercially viable therapies.
How does Doug Drew's background benefit Gallant?
Doug Drew's leadership experience in a global veterinary health network provides insights into integrating innovation into clinical practices, enhancing veterinarian support.
